Results 21 to 30 of about 97,638 (260)

Can resistance to either isoniazid or rifampicin predict multidrug resistance tuberculosis (MDR-TB)

Bulletin of the National Research Centre, 2023
Background Previous studies have shown significant differences and lack clarity on whether resistance to either isoniazid or rifampicin can predict multidrug resistance tuberculosis (MDR-TB).
Betty R. Mchaki, Fauster X. Mgaya, Peter P. Kunambi, Mecky I. Matee   +3 more
doaj   +1 more source

Selective Pressure by Rifampicin Modulates Mutation Rates and Evolutionary Trajectories of Mycobacterial Genomes

Microbiology Spectrum, 2023
Resistance to the frontline antibiotic rifampicin constitutes a challenge to the treatment and control of tuberculosis. Here, we analyzed the mutational landscape of Mycobacterium smegmatis during long-term evolution with increasing concentrations of ...
E. Cebrián-Sastre, A. Chiner-Oms, R. Torres-Pérez, I. Comas, J. C. Oliveros, J. Blázquez, A. Castañeda-García   +6 more
doaj   +1 more source

Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis

BMC Infectious Diseases, 2022
Introduction Periprosthetic joint infections (PJI) are a major complication in joint-arthroplasty. Rifampicin is often used as an additional agent to treat PJI, because it penetrates bacterial biofilms.
Uta S. Koepf, Sebastian Scheidt, Gunnar T. R. Hischebeth, Christian P. Strassburg, Dieter C. Wirtz, Thomas M. Randau, Philipp Lutz   +6 more
doaj   +1 more source

Identification, Genotyping and Antimicrobial Susceptibility Testing of Brucella spp. Isolated from Livestock in Egypt [PDF]

, 2019
Brucellosis is a highly contagious zoonosis worldwide with economic and public health impacts. The aim of the present study was to identify Brucella (B.) spp. isolated from animal populations located in different districts of Egypt and to determine their
El-Adawy, Hosny, Elschner, Mandy C., Khan, Aman Ullah, Melzer, Falk, Moawad, Amira A., Neubauer, Heinrich, Ramadan, Eman Shawkat, Roesler, Uwe, Sayour, Ashraf E., Shell, Waleed S.   +9 more
core   +1 more source

Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium [PDF]

Journal of Antimicrobial Chemotherapy, 2007
In a previous study, we observed marked synergy between daptomycin and rifampicin against 73% of rifampicin-resistant, vancomycin-resistant Enterococcus faecium (VRE), with approximately 100-fold reductions in rifampicin MICs observed at one-eighth to one-fourth daptomycin MIC.
Kenneth H, Rand, Herbert J, Houck, Jared A, Silverman   +2 more
openaire   +2 more sources

Resistance to rifampicin: a review [PDF]

The Journal of Antibiotics, 2014
Resistance to rifampicin (RIF) is a broad subject covering not just the mechanism of clinical resistance, nearly always due to a genetic change in the β subunit of bacterial RNA polymerase (RNAP), but also how studies of resistant polymerases have helped us understand the structure of the enzyme, the intricacies of the transcription process and its ...
openaire   +2 more sources

Detecting rifampin and isoniazid resistance in Mycobacterium tuberculosis direct from patient sputum using an automated integrated system

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022
While there has been progress in detection of drug resistant tuberculosis globally, WHO estimates only about half of the patients with bacteriologically confirmed tuberculosis were tested for rifampicin resistance over the past two years.
Rebecca E. Colman, Christopher Hagan, Peter Chiles, Marva Seifert, Donald G. Catanzaro, Alexander V. Kukhtin, Ryan Norville, Laura Hauns, Arial Bueno, Rebecca C. Holmberg, Christopher G. Cooney, Timothy C. Rodwell   +11 more
doaj   +1 more source

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy [PDF]

, 2016
Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after ...
Anthony, Richard, Bratschi, Martin W., Cambau, Emmanuelle, Cavaliero, Arielle, Kasang, Christa, Mieras, Liesbeth, Perera, Geethal, Reichman, Lee, Richardus, Jan Hendrik, Saunderson, Paul, Steinmann, Peter, van Brakel, Wim, van den Broek, Jacques, Yew, Wing Wai   +13 more
core   +6 more sources

Early mortality during rifampicin-resistant TB treatment

The International Journal of Tuberculosis and Lung Disease, 2022
BACKGROUND: Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality due to rifampicin-resistant TB (RR-TB).METHODS: This was a retrospective cohort study to assess 6-month mortality among RR-TB patients diagnosed between 2008 and 2019 ...
Mohr-Holland, E., Daniels, J., Reuter, A., Rodriguez, C. A., Mitnick, C., Kock, Y., Cox, V., Furin, J., Cox, H.   +8 more
openaire   +2 more sources

Global prevalence of resistance to rifampicin in Mycobacterium leprae: A meta-analysis

Journal of Global Antimicrobial Resistance, 2022
Objectives: As the only bactericidal drug in multidrug therapy is rifampicin, monitoring of antimicrobial resistance is important in leprosy patients. Therefore, we conducted a meta-analysis on the resistance of Mycobacterium leprae (M.
Chen Wang, Ziwei Wu, Haiqin Jiang, Ying Shi, Wenyue Zhang, Mengyan Zhang, Hongsheng Wang   +6 more
doaj   +1 more source